ADVOCACY
EHA
Helping to shape the EU health landscape
EHA is the increasingly powerful voice of hematologists at the EU health policy stage. We involve hematologists in the design, revision, and implementation of EU legislation and regulatory frameworks that impact the field.
The central theme on EHA's advocacy agenda is to help shape affordable and equitable access to innovative therapies for patients across Europe. We also seek to increase support for hematology research by advocating for better EU research policies and for more funding opportunities and partnerships.
To advance these goals and optimize the overall regulatory environment for researchers, diagnosticians, and clinicians in hematology, EHA is an active and constructive partner of the EU institutions. We collaborate with national hematology societies and other medical associations, patient organizations, industry federations, and other stakeholders.
In 2023, EHA...
...engaged with EU policymakers on revision of the EU pharmaceutical legislation. For EHA’s positions on Unmet Medical Needs, Hospital Exemptions and other topics of special importance for hematology, click here
...joined the EU Health Technology Assessment (HTA) Stakeholder Network, to help shape implementation of the HTA Regulation;
...was selected for the permanent advisory group of the ACT EU multistakeholder platform in which regulators and stakeholders join forces to shape the EU regulatory framework for clinical trials;
...worked closely with the European Medicines Agency, providing expert input for different working parties, regulatory processes and the agency’s new hematology office;
...played a prominent role in EU-funded projects. In SUPPLY, EHA led the development of recommendations on the clinical use of immunoglobulins and their prioritization in times of crisis. In ASCERTAIN, EHA oversees stakeholder involvement to ensure that the consortium’s deliverables – new policy support tools for cost-effectiveness, pricing and reimbursement – will benefit from broad and balanced expert input.
BACK UP
ADVOCACY
EHA
BACK UP
In 2023, EHA...
...engaged with EU policymakers on revision of the EU pharmaceutical legislation. For EHA’s positions on Unmet Medical Needs, Hospital Exemptions and other topics of special importance for hematology, click here
...joined the EU Health Technology Assessment (HTA) Stakeholder Network, to help shape implementation of the HTA Regulation;
...was selected for the permanent advisory group of the ACT EU multistakeholder platform in which regulators and stakeholders join forces to shape the EU regulatory framework for clinical trials;
...worked closely with the European Medicines Agency, providing expert input for different working parties, regulatory processes and the agency’s new hematology office;
...played a prominent role in EU-funded projects. In SUPPLY, EHA led the development of recommendations on the clinical use of immunoglobulins and their prioritization in times of crisis. In ASCERTAIN, EHA oversees stakeholder involvement to ensure that the consortium’s deliverables – new policy support tools for cost-effectiveness, pricing and reimbursement – will benefit from broad and balanced expert input.
To advance these goals and optimize the overall regulatory environment for researchers, diagnosticians, and clinicians in hematology, EHA is an active and constructive partner of the EU institutions. We collaborate with national hematology societies and other medical associations, patient organizations, industry federations, and other stakeholders.
The central theme on EHA's advocacy agenda is to help shape affordable and equitable access to innovative therapies for patients across Europe. We also seek to increase support for hematology research by advocating for better EU research policies and for more funding opportunities and partnerships.
EHA is the increasingly powerful voice of hematologists at the EU health policy stage. We involve hematologists in the design, revision, and implementation of EU legislation and regulatory frameworks that impact the field.
Helping to shape the EU health landscape